- U.S. Centers for Medicare & Medicaid Services (CMS) reimbursement expands access of the FreeStyle Libre 2 system to Medicare patients[1] to better manage their diabetes - The FreeStyle Libre 2 ...
Pharmaceutical and med device giant Abbott (NYSE: ABT) said today that it had received approval from the Food and Drug Administration (FDA) for its next-generation integrated continuous glucose ...
The FDA has approved the FreeStyle® Libre 2 integrated continuous glucose monitoring system (Abbott) for adults and children ≥4 years of age with diabetes. The Food and Drug Administration (FDA) has ...
MISSISSAUGA, ON, Dec. 17, 2024 /CNW/ -- Abbott (NYSE: ABT) today announced that the Government of Alberta has added Abbott's FreeStyle Libre 2 * flash glucose monitoring system to the Alberta Drug ...
ABBOTT PARK, Ill., June 22, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the French health authority has approved the expansion of reimbursement coverage for its FreeStyle Libre 2 ...
"The best healthcare solution is the one that helps the most people, which is why we designed our FreeStyle Libre portfolio with access and affordability in mind from the very beginning," said ...